Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis

Virology

Volumn 224, Issue 1, 1996, Pages 268-275

  Schnölzer, Martina ^c   Rackwitz, Hans Richard ^b   Gustchina, Alla ^a   Laco, Gary S ^b   Wlodawer, Alexander ^a   Elder, John H ^b   Kent, Stephen B H ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; SYNTHETIC PEPTIDE;

ARTICLE; DRUG DESIGN; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SPECIFICITY; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; SYNTHESIS;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0010738069     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0528     Document Type: Article

References (38)

1. Ackley, C. D., Yamamoto, J. K., Levy, N., Pedersen, N. C., and Cooper, M. D. (1990). Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J. Virol. 64, 5652-5655.
2. Ashorn, P., McQuade, T. J., Thaisrivongs, S., Tomasselli, A. G., Tarpley, W. G., and Moss, B. (1990). An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Natl. Acad. Sci. USA 87, 7472-7476.
3. Baboonian, C., Dalgleish, A., Bountiff, L., Gross, J., Oroszlan, S., Rickett, G., Smith-Burchnell, C., Troke, P., and Merson, J. (1991). HIV-1 proteinase is required for synthesis of pro-viral DNA. Biochem. Biophys. Res. Commun. 179, 17-24.
4. Barlough, J. E., Ackley, C. D., George, J. W., Levy, N., Acevedo, R., Moore, P. F., Rideout, B. A., Cooper, M. D., and Pedersen, N. C. (1991). Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J. Acquir. Immune Defic. Syndr. 4, 219-227.
5. Crawford, S., and Goff, S. P. (1985). A deletion mutation in the 5′ part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J. Virol. 53, 899-907.
6. Dow, S. W., Poss, M. L., and Hoover, L. A. (1990). Feline immunodeficiency virus: a neurotropic lentivirus. J. Acquir. Immune Defic. Syndr. 3, 658-668.
7. El-Farrash, M. A., Kuroda, M. J., Kitazaki, T., Masuda, T., Kalo, K., Hatanaka, M., and Harada, S. (1994). Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J. Virol. 68, 233-239.
8. Elder, J. H., Schnolzer, M., Hasselkus-Light, C. S., Henson, M., Lerner, D. A., Phillips, T. R., Wagaman, P. C., and Kent, S. B. (1993). Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus. J. Virol. 67, 1869-1876.
9. Griffiths, J. T., Phylip, L. H., Konvalinka, J., Strop, P., Gustchina, A., Wlodawer, A., Davenport, R. J., Briggs, R., Dunn, B. M., and Kay, J. (1992). Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic-or -aromatic*pro-cleavage sites. Biochemistry 31, 5193-5200.
10. Huff, J. R. (1991). HIV protease: a novel chemotherapeutic target for AIDS. [Review] J. Med. Chem. 34, 2305-2314.
11. Hyland, L. J., Tomaszek, T. A. Jr., and Meek, T. D. (1991a). Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 30, 8454-8463.
12. 18O isotope exchange. Biochemistry 30, 8441-8453.
13. Ido, E., Han, H. P., Kezdy, F. J., Tang, J. (1991). Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J. Biol. Chem. 266, 24359-24366.
14. Ishida, T., Washizu, T., Toriyabe, K., Motoyoshi, S., Tomoda, I., and Pedersen, N. C. (1989) Feline immunodeficiency virus infection in cats of Japan. J. Am. Vet. Med. Assoc. 194, 221-225.
15. Katoh, I., Yoshinaka, Y., Rein, A., Shibuya, M., Odaka, T., and Oroszlan, S. (1985). Murine leukemia virus maturation: Protease region required for conversion from "immature" to "mature" core form and for virus infectivity. Virology 145, 280-292.
16. Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., Scolnick, E. M., and Sigal, I. S. (1988). Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85, 4686-4690.
17. Kramer, R. A., Schaber, M. D., Skalka, A. M., Ganguly, K., Wong-Staa, I. F., and Reddy, E. P. (1986). HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science. 231, 1580-1584.
18. Miller, M., Jaskolski, M., Rao, J. K., Leis, J., and Wlodawer, A. (1989). Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature. 337, 576-579.
19. Miller, M., Schneider, J., Sathyanarayana, B. K., Toth, M. V., Marshall, G. R., Clawson, L., Selk, L., Kent, S. B., and Wlodawer, A. (1989). Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science. 246, 1149-1152.
20. Mitsuya, H., Yarchoan, R., and Broder, S. (1990). Molecular targets for AIDS therapy. [Review] Science. 249, 1533-1544.
21. Olmsted, R. A., Hirsch, V. M., Purcell, R. H., and Johnson, P. R. (1989). Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc. Natl. Acad. Sci. USA 86, 8088-8092.
22. Otto, M. J., Garber, S., Winslow, D. L., Reid, C. D., Aldrich, P., Jadhav, P. K., Patterson, C. E., Hodge, C. N., and Cheng, Y. S. (1993). In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc. Natl. Acad. Sci. USA 90, 7543-7547.
23. Pedersen, N. C., Ho, E. W., Brown, M. L., and Yamamoto, J. K. (1987). Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235, 790-793.
24. Phillips, T. R., Talbott, R. L., Lamont, C., Muir, S., Lovelace, K., and Elder, J. H. (1990). Comparison of two host cell range variants of feline immunodeficiency virus. J. Virol. 64, 4605-4613.
25. Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A., Baumeister, K., et al. (1985). Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-284.
26. Sarin, V. K., Kent, S. B., Tam, J. P., and Merrifield, R. B. (1981). Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction. Anal. Biochem. 117, 147-157.
27. Schnölzer, M., Alewood, P., Jones, A., Alewood, D., and Kent, S. B. (1992a). In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Peptide Protein Res. 40, 180-193.
28. Schnölzer, M., Jones, A., Alewood, P. F., and Kent, S. B. (1992b). lonspray tandem mass spectrometry in peptide synthesis: structural characterization of minor by-products in the synthesis of ACP(65-74). Anal. Biochem. 204, 335-343.
29. Slee, D. H., Laslo, K. L., Elder, J. H., Oilman, I. R., Gustchina, A., Kervinen, J., Zdanov, A., Wlodawer, A., and Wong, C.-H. (1995). Selectivity in the inhibition of HIV and FIV protease: inhibitory and mechanistic studies of pyrrolidine-containing α-keto amide and hydroxyethylamine core structures. J. Am. Chem. Soc. 117, 11867-11878.
30. Talbott, R. L., Sparger, E. E., Lovelace, K. M., Fitch, W. M., Pedersen, N. C., Luciw, P. A., and Elder, J. H. (1989). Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc. Natl. Acad. Sci. USA 86, 5743-5747.
31. Toth, M. V., and Marshall, G. R. (1990). A simple, continuous fluorometric assay for HIV protease. Int. J. Peptide Protein Res. 36, 544-550.
32. Vacca, J. P., Dorsey, B. D., Schleif, W. A., Levin, R. B., McDaniel, S. L., Darke, P. L, Zugay, J., Quintero, J. C., Blahy, O. M., Roth E. et al. (1994). L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91, 4096-4100.
33. von der Helm, K., Gurtler, L., Eberle, J., and Deinhardt, F. (1989). Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A. FEBS Lett. 247, 349-352.
34. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B. K., Baldwin, E., Weber, I. T., Selk, L. M., Clawson, L., Schneider, J., and Kent, S. B. (1989). Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245, 616-621.
35. Wondrak, E. M., Louis, J. M., and Oroszlan, S. (1991). The effect of salt on the Michaelis-Menten constant of the HIV-1 protease correlates with the Hofmeister series. FEBS Lett. 280, 344-346.
36. Yamamoto, J. K., Hansen, H., Ho, E. W., Morishita, T. Y., Okuda, T., Sawa, T. R., Nakamura, R. M., and Pedersen, N.C. (1989). Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. J. Am. Vet. Med. Assoc. 194, 213-220.
37. Yamamoto, J. K., Okuda, T., Ackley, C. D., Louie, H., Pembroke, E., Zochlinski, H., Munn, R. J., and Gardner, M. B. (1991). Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Hum. Retroviruses 7, 911-922.
38. Yamamoto, J. K., Sparger, E., Ho, E. W., Andersen, P. R., O'Connor, T. P., Mandell, C. P., Lowenstine, L., Munn, R., and Pedersen, N. C. (1988). Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am. J. Vet. Res. 49, 1246-1258.